Loading company…
Seattle-based developer of scalable single-cell sequencing technologies, including the Evercode series.
Founded in 2018 and based in Seattle, US, Parse Biosciences develops scalable single-cell sequencing technologies, mainly through its Evercode series, which supports research in immunology and cancer. Its Evercode WT kits allow analysis of up to 5 million cells in one experiment, and it sells to academic institutions, biotech and pharmaceutical companies. In November 2025 Qiagen N.V. agreed to fully acquire the company from its investors for USD 225 million in cash, with up to USD 55 million in additional contingent payments tied to milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in